dementia Archives

Insurance By Bob Herman

UnitedHealthcare restricts coverage of Aduhelm, following Medicare

Biotech By Adam Feuerstein and Damian Garde

Biogen board slashes CEO’s bonus as Aduhelm sales and overall business struggle

Politics By Nicholas Florko

Medicare’s Brooks-LaSure expects restrictions on accelerated approval drugs, like those for Aduhelm, to be ‘very rare’

D.C. Diagnosis By Nicholas Florko

The next battle in the never-ending war over Aduhelm

D.C. Diagnosis By Nicholas Florko

Before Aduhelm, Billy Dunn was a superstar at the FDA

Politics By Nicholas Florko

Lawmakers face off about the future of the FDA’s accelerated approval pathway

Politics By Rachel Cohrs

Medicare premiums could decrease ‘soon,’ after decision on Alzheimer’s drug Aduhelm

Biotech By Matthew Herper

Biogen publishes data on its Alzheimer’s drug in a little-known journal

Biotech By Adam Feuerstein and Damian Garde

With Aduhelm in limbo, Biogen starts laying off employees

Biotech By Damian Garde

Awaiting ‘definitive’ Alzheimer’s drug data, Roche and Genentech launch ambitious new study

First Opinion By Rhoda Au

Improving diversity in Alzheimer’s research can help update the ‘gold standard’ for all medical research

Adam's Take By Adam Feuerstein

An FDA ruling on Cassava’s Alzheimer’s drug leaves bulls and bears waiting for more

Biotech By Nicholas Florko

Biogen pushes back on Medicare’s limits on Alzheimer’s drug coverage — and advances a counteroffer

D.C. Diagnosis By Nicholas Florko

A no good, very bad week for Biden’s science agenda

Politics By Nicholas Florko

The unexpected forces behind thousands of comments about Medicare’s limits on a new Alzheimer’s drug

Politics By Nicholas Florko

Lawmakers grill key FDA official over controversial Alzheimer’s drug approval

Biotech By Damian Garde and Adam Feuerstein

Biogen sells stake in Samsung venture for $2.3 billion

Pharmalot By Ed Silverman

Pharmalittle: Biden administration used hospital funds to buy Covid vaccines and drugs; a cancer drug may help combat HIV

The Pharmalot View By Ed Silverman

If the Biogen CEO were truly ‘courageous,’ he would live with the Medicare decision

Politics By Rachel Cohrs

No one has any idea how much money seniors could pay for new Alzheimer’s drug

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: #JPM22 in review, Biogen’s worsening fortunes, & the future of RNA drugs

Exclusive By Damian Garde and Adam Feuerstein

With its Alzheimer’s drug in turmoil, Biogen eyes a list of potential acquisitions

Health By Nicholas Florko

With its Aduhelm proposal, Medicare is stepping into a heated debate about how best to improve equity in Alzheimer’s treatment

Pharmalot By Ed Silverman, Rachel Cohrs and Nicholas Florko

The biggest losers from Medicare’s decision on Aduhelm may be Biogen’s competitors

Matt's Take By Matthew Herper

Most Read

Will Biogen sue Medicare over its restrictions on the Alzheimer’s drug, Aduhelm? And other big legal questions about the decision

CMS made the wrong decision on Aduhelm. But there might be a silver lining

Medicare got it right: Unproven Alzheimer’s drug would have threatened the financial stability of 60 million Americans

Medicare finalizes its restrictions on new Alzheimer’s drug, despite pressure from drugmakers

Faced with high drug prices, seniors are abandoning cancer drugs at the pharmacy

Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies

Califf admits controversy over FDA’s Alzheimer’s drug decision impacted experts’ trust in the agency

With pharma still struggling in Alzheimer’s, health tech companies want a swing

All Coverage

UnitedHealthcare restricts coverage of Aduhelm, following Medicare

Biogen board slashes CEO’s bonus as Aduhelm sales and overall business struggle

Medicare’s Brooks-LaSure expects restrictions on accelerated approval drugs, like those for Aduhelm, to be ‘very rare’

The next battle in the never-ending war over Aduhelm

Before Aduhelm, Billy Dunn was a superstar at the FDA

Lawmakers face off about the future of the FDA’s accelerated approval pathway

Medicare premiums could decrease ‘soon,’ after decision on Alzheimer’s drug Aduhelm

Biogen publishes data on its Alzheimer’s drug in a little-known journal

With Aduhelm in limbo, Biogen starts laying off employees

Awaiting ‘definitive’ Alzheimer’s drug data, Roche and Genentech launch ambitious new study

Improving diversity in Alzheimer’s research can help update the ‘gold standard’ for all medical research

An FDA ruling on Cassava’s Alzheimer’s drug leaves bulls and bears waiting for more

Biogen pushes back on Medicare’s limits on Alzheimer’s drug coverage — and advances a counteroffer

A no good, very bad week for Biden’s science agenda

The unexpected forces behind thousands of comments about Medicare’s limits on a new Alzheimer’s drug

Lawmakers grill key FDA official over controversial Alzheimer’s drug approval

Biogen sells stake in Samsung venture for $2.3 billion

Pharmalittle: Biden administration used hospital funds to buy Covid vaccines and drugs; a cancer drug may help combat HIV

If the Biogen CEO were truly ‘courageous,’ he would live with the Medicare decision

No one has any idea how much money seniors could pay for new Alzheimer’s drug

Listen: #JPM22 in review, Biogen’s worsening fortunes, & the future of RNA drugs

With its Alzheimer’s drug in turmoil, Biogen eyes a list of potential acquisitions

With its Aduhelm proposal, Medicare is stepping into a heated debate about how best to improve equity in Alzheimer’s treatment

The biggest losers from Medicare’s decision on Aduhelm may be Biogen’s competitors

Why Biogen’s Medicare mess is bad for the pharmaceutical industry